Omalizumab

Category: biologic

Aliases: Xolair, anti-IgE mAb

Pharmacological Mechanism

Humanised IgG1κ mAb binding free IgE at the Cε3 domain (the FcεRI-binding site) → forms soluble trimeric/hexameric complexes that cannot engage FcεRI on mast cells/basophils. Downregulates FcεRI expression over weeks. Chronic suppression of allergic cascade.

Half-Life (t½)

SC: 624h

Dosing Guidelines

Target Organ Systems